Nav: Home

Novel tracer safely and effectively maps sentinel lymph nodes in breast cancer patients

August 17, 2016

Reston, Va. - Determining whether breast cancer has spread to sentinel lymph nodes (SLN) is key to prognosis and treatment, making SLN mapping critical. The blue dyes commonly used to identify SLNs spread quickly to other nodes and is poorly retained by the SLNs (less than five minutes). This requires the surgeon to identify SLNs quickly. Allergic reaction to the dyes has also been a concern.

A recent study by researchers at Peking University Cancer Hospital & Institute, Beijing, China, demonstrates the effectiveness and safety of a new SLN radiotracer, Tc-99m-rituximab, which is well retained by SLNs. The tracer targets the antigen CD20, which is expressed extensively in lymph nodes. The study is published in the August issue of The Journal of Nuclear Medicine.

"The advantage of Tc-99m-rituximab is its uniform molecular weight and molecular size. It does not escape easily from SLNs to the second echelon lymph nodes," explains Zhi Yang, PhD, chair of the Department of Nuclear Medicine at Beijing Cancer Hospital. "This results in clear SLN imaging in patients and the high success rate of lymphoscintigraphy. In addition, technical factors, such as the injection dose, injection volume and injection site, can be well controlled."

This first study of Tc-99m-rituximab as a radiotracer for SLN imaging used lymphoscintigraphy in both preoperative and intra-operative breast cancer patients. It included 2,317 patients with primary breast cancer who underwent both lymphoscintigraphy and SLN biopsy.

In the initial study of 100 of these patients, who were randomly selected (median age 46, ranging from 27 to 73), the detection rate for SLN lymphoscintigraphy by injection of Tc-99m-rituximab was 100 percent. SLNs from the 100 patients were then harvested, guided by a hand-held gamma detecting probe, and biopsied with a success rate also of 100 percent. Of the following 2,217 patients studied, the detection/success rate was 98.8 percent for lymphoscintigraphy and 99.9 percent for SLN biopsy.

While the combination of blue dye and a radiotracer has been shown to be a superior method of detecting SLNs in breast cancer patients with an identification rate of 89 to 97 percent, this first study of the use of Tc-99m-rituximab alone demonstrates that it provides even better detection and avoids possible blue dye side effects. The tracer may have broader applications as well. Dr. Yang points out, "This radiotracer has also shown promising results in lymphoscintigraphy of melanoma."

According to the National Cancer Institute, in 2016 an estimated 246,660 new cases of breast cancer are expected to be diagnosed in U.S. women, and approximately 40,450 American women will die from breast cancer this year.
-end-
Authors of the article "Clinical Evaluation of 99mTc-Rituximab for Sentinel Lymph Node Mapping in Breast Cancer Patients" include Nan Li, Xuejuan Wang, Baohe Lin, Hua Zhu, Cheng Liu, Xiaobao Xu, Yan Zhang, Shizhen Zhai, Tao OuYang, Jinfeng Li, and Zhi Yang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.

Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or lcallahan@snmmi.org. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org

Society of Nuclear Medicine

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
More Breast Cancer News and Breast Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Teaching For Better Humans
More than test scores or good grades — what do kids need to prepare them for the future? This hour, guest host Manoush Zomorodi and TED speakers explore how to help children grow into better humans, in and out of the classroom. Guests include educators Olympia Della Flora and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#535 Superior
Apologies for the delay getting this week's episode out! A technical glitch slowed us down, but all is once again well. This week, we look at the often troubling intertwining of science and race: its long history, its ability to persist even during periods of disrepute, and the current forms it takes as it resurfaces, leveraging the internet and nationalism to buoy itself. We speak with Angela Saini, independent journalist and author of the new book "Superior: The Return of Race Science", about where race science went and how it's coming back.